NewAmsterdam Pharma Co N.V. (NAMS) Executive Compensation
NewAmsterdam Pharma Co N.V. (NAMS) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: NAMS
CIK: 1936258
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: P7
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Deloitte Accountants B.V.
Auditor SinceSince 6/30/2022 12:00:00 AM
Lead Engagement PartnerAloisia Zwama-Bombeeck
Audit LocationEindhoven, Netherlands
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-10-02 | 2026-09-30 | 4 | 0001193125-26-412431 | View SEC Doc Filr Page |
| 8-K | 2026-09-29 | 2026-09-29 | 8-K | 0001193125-26-406063 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-09-22 | — | SCHEDULE 13D/A Filing | 0001231919-26-001215 | View SEC Doc Filr Page |
| 8-K | 2026-09-21 | 2026-09-21 | 8-K | 0001193125-26-396716 | View SEC Doc Filr Page |
| 4 | 2026-09-15 | 2026-09-14 | 4 | 0001193125-26-391985 | View SEC Doc Filr Page |
| 4 | 2026-09-09 | 2026-09-04 | 4 | 0001193125-26-386508 | View SEC Doc Filr Page |
| 4 | 2026-09-03 | 2026-09-01 | 4 | 0001193125-26-381953 | View SEC Doc Filr Page |
| 144/A | 2026-08-25 | — | 144/A Filing | 0001968582-26-000878 | View SEC Doc Filr Page |
| 4 | 2026-08-25 | 2026-08-24 | 4 | 0001193125-26-365202 | View SEC Doc Filr Page |
| 144 | 2026-08-24 | — | 144 Filing | 0001968582-26-000868 | View SEC Doc Filr Page |
| 8-K/A | 2026-08-14 | 2026-07-16 | 8-K/A | 0001193125-26-352233 | View SEC Doc Filr Page |
| 3 | 2026-08-14 | 2026-08-10 | 3 | 0001193125-26-352209 | View SEC Doc Filr Page |
| 8-K | 2026-08-14 | 2026-08-10 | 8-K | 0001193125-26-352186 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-06 | — | SCHEDULE 13G/A Filing | 0000315066-26-002082 | View SEC Doc Filr Page |
| 8-K | 2026-08-05 | 2026-08-05 | 8-K | 0001193125-26-333827 | View SEC Doc Filr Page |
| 10-Q | 2026-08-05 | 2026-06-30 | 10-Q | 0001193125-26-333824 | View SEC Doc Filr Page |
| 8-K | 2026-07-24 | 2026-07-24 | 8-K | 0001193125-26-315163 | View SEC Doc Filr Page |
| 8-K | 2026-07-22 | 2026-07-16 | 8-K | 0001193125-26-312390 | View SEC Doc Filr Page |
| 4 | 2026-07-22 | 2026-07-20 | 4 | 0001193125-26-312387 | View SEC Doc Filr Page |
| 4 | 2026-06-24 | 2026-06-22 | 4 | 0001193125-26-281062 | View SEC Doc Filr Page |
| S-8 | 2026-06-05 | — | S-8 | 0001193125-26-259794 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-06-04 | — | SCHEDULE 13G/A Filing | 0001422849-26-000108 | View SEC Doc Filr Page |
| 8-K | 2026-06-03 | 2026-06-02 | 8-K | 0001193125-26-254615 | View SEC Doc Filr Page |
| 4 | 2026-05-27 | 2026-05-26 | 4 | 0001193125-26-241983 | View SEC Doc Filr Page |
| 144 | 2026-05-26 | — | 144 Filing | 0001968582-26-000491 | View SEC Doc Filr Page |